What is NOXXON Pharma?
Founded in 1997 and headquartered in Berlin, Germany, NOXXON Pharma is a clinical-stage biopharmaceutical company dedicated to advancing novel treatments for cancer. The company's focus on proprietary therapeutics positions it within a critical segment of the healthcare industry, aiming to address unmet medical needs in oncology. Its strategic location in Germany places it within a robust European biotech ecosystem.
How much funding has NOXXON Pharma raised?
NOXXON Pharma has raised a total of $91.7M across 7 funding rounds:
Series B
$23.6M
Series D
$40.4M
Share Placement
$557K
Debt
$15.3M
Stock Offering
$7.8M
Stock Offering
$1.4M
Share Placement
$2.6M
Series B (2000): $23.6M with participation from West Deutsche Landesbank Girozentrale, Excalibur Fund Managers, and Hannover Finanz
Series D (2010): $40.4M, investors not publicly disclosed
Share Placement (2020): $557K, investors not publicly disclosed
Debt (2020): $15.3M featuring Atlas Special Opportunities
Stock Issuance/Offering (2021): $7.8M, investors not publicly disclosed
Stock Issuance/Offering (2021): $1.4M with participation from Kreos Capital Group
Share Placement (2022): $2.7M, investors not publicly disclosed
Key Investors in NOXXON Pharma
Atlas Special Opportunities
Atlas Special Opportunities is an investment entity that has provided debt financing to NOXXON Pharma, indicating a focus on structured financial solutions for companies in development.
Kreos Capital Group
Kreos Capital Group is a finance company specializing in investment services and business management, having previously provided capital to NOXXON Pharma through share placements.
Hannover Finanz
Hannover Finanz is an investment firm that has participated in earlier funding rounds for NOXXON Pharma, suggesting a history of supporting the company's growth and development.
What's next for NOXXON Pharma?
The recent major strategic investment provides NOXXON Pharma with substantial capital to advance its clinical pipeline and further its research and development initiatives. This infusion of financing is expected to accelerate the company's growth trajectory, potentially enabling key milestones in drug development and market entry. The company's ability to attract significant backing indicates strong investor confidence in its therapeutic approach and market potential.
See full NOXXON Pharma company page
